GenBioPro & Abbott Laboratories
3 shared events · Importance 3 · Last updated May 16, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Domestic
GenBioPro: GenBioPro, a manufacturer of a generic version of mifepristone, also received temporary relief from Samuel Alito's order. The company appealed to the United States — Supreme Court of the United States, stating that the 5th Circuit's decision 'unleashed regulatory chaos' and threatened access to mifepristone nationwide.
Abbott Laboratories: Abbott Laboratories, the maker of mifepristone, received temporary relief from Samuel Alito's order, allowing continued mail access to the drug. The company appealed to the United States — Supreme Court of the United States to set aside the appellate court's order and expressed concern about the 'immediate confusion and upheaval' caused by the 5th Circuit's decision.
May 04, 2026 · 6 articles
Domestic
GenBioPro: GenBioPro, a manufacturer of a generic version of mifepristone, also filed an emergency appeal, contributing to the United States — Supreme Court of the United States's decision to restore access.
Abbott Laboratories: Abbott Laboratories, the maker of mifepristone, filed an emergency appeal to the United States — Supreme Court of the United States, which led to the temporary restoration of access to the drug.
May 04, 2026 · 52 articles
Regulatory
GenBioPro: GenBioPro, a generic Mifepristone manufacturer, stated that the court's decision ignores the United States — Food and Drug Administration's science and decades of safe use of the drug.
Abbott Laboratories: Abbott Laboratories, a manufacturer of Mifepristone, is a defendant in the lawsuit and has requested a hold on the appeals court's order to seek relief from the United States — Supreme Court of the United States.
May 01, 2026 · 78 articles
NEWSDESK
Explore this relationship live
Track how GenBioPro and Abbott Laboratories interact across events, view sentiment trends, and discover connected entities.
Open Dashboard